Under the auspices of the Gottesfeld-Hohler Memorial Foundation, a Consensus Statement was developed to address the multiple guidelines regarding screening for early-onset preeclampsia (open access summaries of these recommendations can be found below in ‘Related ObG Topics’). This ‘Think Tank Summary’ was comprised of expert participants, including representatives from ACOG, NICHD, SMFM, AIUM, FMF and ISUOG. The Consensus Statement recognizes that while there are differences regarding approach, there is consensus regarding the importance of screening and use of prophylactic aspirin when appropriate. The authors conclude with the following
…it is strongly advised to identify patients at high risk for preeclampsia at least by the guidelines of ACOG, SMFM, the U.S. Preventative Services Task Force, or the Fetal Medicine Foundation criteria.
Offering prophylactic low-dose aspirin starting in the late first or early second trimester, and close scrutiny of these women throughout pregnancy, may help to avert or mitigate the severe complications for the mother, fetus, and neonate that can result from preeclampsia.
Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary
Randomized, double-blind, placebo-controlled trial (RCT)
Delivery with preeclampsia < 37 weeks: Definition of preeclampsia based on International Society for the Study of Hypertension in Pregnancy criteria
Secondary Outcomes: Such as abruption, stillbirth, miscarriage, neonatal morbidity and mortality
Adverse Events: Including maternal, fetal and neonatal
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Competing risks model in screening for preeclampsia by maternal characteristics and medical history
Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation
Please log in to ObGFirst to access the 2T US Atlas